Forsberg Ole, Carlsson Björn, Tötterman Thomas H, Essand Magnus
Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Br J Haematol. 2008 Apr;141(2):188-99. doi: 10.1111/j.1365-2141.2008.07026.x. Epub 2008 Feb 26.
Cytomegalovirus (CMV) reactivation can cause severe complications for transplant patients. Such patients can be protected against CMV-associated diseases through reconstitution of donor-derived CMV-reactive cytolytic and helper T cells. We have developed a strategic protocol for efficient simultaneous generation of CMV-reactive CD8+ and CD4+ T cells ex vivo. The protocol uses peripheral blood lymphocytes (PBLs), antigen-modified mature dendritic cells (DCs) generated in only 3 d and an adenoviral vector encoding the CMV pp65 antigen (Adpp65) both as an endogenous and exogenous source of antigen. PBLs stimulated once with Adpp65-transduced DCs (endogenously expressed pp65) resulted in preferential activation and expansion of pp65-specific CD8+ T cells while PBLs stimulated with DCs pulsed with cell lysate from Adpp65-transduced autologous monocytes (exogenously expressed pp65) yielded pp65-specific CD4+ T cells. Stimulation with double-modified DCs efficiently activated and expanded cytolytic and helper T cells simultaneously. The frequency of T cells producing interferon-gamma in response to pp65 increased after one stimulation on average 9.6-fold to 4.3% for CD8+ T cells and 25.8-fold to 6.5% for CD4+ T cells. This implies that sufficient number of pp65-specific cytolytic and helper T cells for adoptive transfer may be obtained in only 2 weeks.
巨细胞病毒(CMV)再激活可给移植患者带来严重并发症。通过重建供体来源的CMV反应性细胞溶解和辅助性T细胞,可保护此类患者免受CMV相关疾病的侵害。我们已制定了一项策略方案,用于在体外高效同时生成CMV反应性CD8⁺和CD4⁺T细胞。该方案使用外周血淋巴细胞(PBL)、仅在3天内生成的抗原修饰成熟树突状细胞(DC)以及编码CMV pp65抗原的腺病毒载体(Adpp65)作为抗原的内源性和外源性来源。用Adpp65转导的DC(内源性表达pp65)刺激一次的PBL会导致pp65特异性CD8⁺T细胞优先活化和扩增,而用来自Adpp65转导的自体单核细胞的细胞裂解物脉冲处理的DC刺激的PBL(外源性表达pp65)则产生pp65特异性CD4⁺T细胞。用双重修饰的DC刺激可同时有效激活和扩增细胞溶解和辅助性T细胞。在一次刺激后,响应pp65产生干扰素-γ的T细胞频率平均增加,CD8⁺T细胞增加9.6倍至4.3%,CD4⁺T细胞增加25.8倍至6.5%。这意味着仅在2周内就可获得足够数量用于过继转移的pp65特异性细胞溶解和辅助性T细胞。